

FOR THE USE ONLY OF A REGISTERED MEDICAL PRACTITIONER OR A HOSPITAL OR A LABORATORY
Rx

Biphasic Isophane Insulin Injection I.P. 100 IU/ml (r-DNA origin)

Wosulin® 30/70

3ml multi-dose
cartridge

100 IU/ml

30/70
Monocomponent
Insulin HUMAN

For **SC** use only

WOCKHARDT

1. Generic Name
Biphasic Isophane Insulin Injection IP 100 IU/ml (r-DNA origin)
Monocomponent Insulin Human

2. Qualitative and quantitative composition
Each mL contains
Human Insulin IP100 IU

(30% Soluble Insulin Injection and 70% Isophane Insulin Injection)
m-Cresol USP0.16% w/v (as preservative)

Phenol IP0.65% w/v (as preservative)
Water for Injections IPq.s

3. Dosage form and strength
It is a 3 mL cartridge containing 100 IU/mL Biphasic Isophane Insulin Injection for subcutaneous use.

4. Clinical particulars

4.1 Therapeutic indication
Biphasic Isophane Insulin Injection is indicated for the following:

• For the treatment of type-I diabetes mellitus
• For the treatment of type-II diabetes who are not adequately controlled by diet and/or oral hypoglycaemic agent

• For the initial stabilization of Type II diabetes patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and in diabetes during pregnancy.

4.2 Posology and method of administration

Inspect WOSULIN-30/70 visually before use. It should not contain particulate matter and should appear uniformly cloudy after mixing. Do not use WOSULIN-30/70 if particulate matter is seen. Do not mix WOSULIN-30/70 with any other insulins or diluents.

WOSULIN-30/70 should only be administered subcutaneously. Administer in the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next.

Do not administer WOSULIN-30/70 intravenously or intramuscularly and do not use WOSULIN-30/70 in an insulin infusion pump.

The average range of total insulin requirement for maintenance in type 1 diabetic patients ranges between 0.5 to 1 IU/kg. For Neonates it is 0.01 – 0.1 IU/kg/hr by continuous infusion or SC 0.1 – 0.2 IU/kg 6 – 12 hr. For children it is 0.5 – 1 IU/kg/24hr (Adjust doses to blood glucose and haemoglobin A1c results) and for adolescents it is 0.8 – 1.2 IU/kg/24hr. Further, in insulin resistance, the daily requirement of insulin may be substantially higher. In patients with type 2 diabetes, the requirements of insulin are lower i.e. approximately 0.3-0.6 IU/kg/day. Individualize and adjust the dosage of WOSULIN-30/70 based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.

Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), and changes in renal or hepatic function or during acute illness.

The proportion of rapid acting and long acting insulin is fixed in premixed insulin such as WOSULIN-30/70. Independent adjustment of the basal or prandial dose is not possible when using premixed insulin.

WOSULIN-30/70 should be given subcutaneously approximately 30-45 minutes before a meal.

INSTRUCTIONS FOR USE

a. Disinfect the rubber surface of the insulin Cartridge with alcohol. Insert the Cartridge in the Pen as shown in the mypen® 2 instruction manual. Before inserting the Cartridge, inspect the Cartridge of WOSULIN-30/70 after removing from the sealed pack for any crystallization, clumping or discoloration. If present, discard and use a new Cartridge.

b. Before you insert the Cartridge into the mypen® 2, roll it between your palms at least 10 times. (Ref Fig. 1).

Then hold the Cartridge at one end and move between position "A" to position "B" slowly so that the glass ball travels from one end of the Cartridge to the other end. (Ref Fig. 2).

This must be done at least 10 times until the liquid appears uniformly cloudy or milky. Discard the Cartridge if clumps are seen after mixing.

c. If the Cartridge is already inside the mypen® 2, turn the Pen up and down gently at least 10 times until the liquid appears uniformly cloudy or milky. This has to be done before each injection. (Ref Fig. 3).

d. After you attach the needle, dial 2 units on the dose selector to remove any air that may be inside the needle.

e. Wash your hands and clean the skin with alcohol where the injection is to be made.

f. With one hand, lightly pinch up the skin, insert the needle as advised by your doctor or educator. Push and hold the release button of the Pen. Count to 10 and pull out the needle. Do not massage the area as this may cause back leakage of insulin.

g. Dispose off the needle in the recommended way.

h. For additional information, read the instruction manual of mypen® 2 and also log on to www.wockhardt diabetes.com

4.3 Contraindications
WOSULIN-30/70 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to WOSULIN-30/70 or any of its excipients.

4.4 Special warnings and precautions for use
Needles or syringes must never be reused or shared between patients. Sharing poses a risk for transmission of blood-borne pathogens.

Any change in insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH, analog, etc.), species, or method of administration may result in the need for a change in dosage.

Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including WOSULIN-30/70, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

Hypoglycemia: Hypoglycemia is the most common adverse reaction of all insulin therapies, including WOSULIN-30/70. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death.

Adjustment of dosage of any insulin may be necessary if patients change their physical activity or their usual meal plan. Insulin requirements may be altered during illness, emotional disturbances, or other stresses. Concomitant antihyperglycemic agents may need to be adjusted. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia. As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Hypersensitivity: Diabetic Ketoacidosis, and Hyperosmolar Non-Ketotic Syndrome: Hypersensitivity: Hypersensitivity, or hyperosmolar coma may develop if the patient takes less WOSULIN-30/70 than needed to control blood glucose levels. This could be due to increases in insulin demand during illness or infection, neglect of diet, omission or improper administration of prescribed insulin doses or use of drugs that affect glucose metabolism or insulin sensitivity.

Hypokalemia: Insulin stimulates potassium movement into the cells, possibly leading to hypokalemia, that left untreated may cause respiratory paralysis, ventricular arrhythmia, and death. Since intravenously administered insulin has a rapid onset of action, increased attention to hypokalemia is necessary. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including WOSULIN-30/70. Localized reactions and generalized myalgias have been reported with the use of metacresol as an injectable excipient.

4.5 Drug interactions
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

Drugs that may increase the blood-glucose-lowering effect of WOSULIN-30/70 and susceptibility to hypoglycemia: Oral antihyperglycemic agents, salicylates, sulfa antibiotics, certain antidepressants (monoamine oxidase inhibitors), selective serotonin reuptake inhibitors (SSRIs), pramipexole, disopyramide, fibrates, fluoxetine, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, beta-adrenergic blockers, inhibitors of pancreatic function (e.g., octreotide), and alcohol.

Drugs that may reduce the blood-glucose-lowering effect: Corticosteroids, isoniazid, certain lipid-lowering drugs (e.g., niacin), estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents, somatropin, atypical antipsychotics, glucagon, protease inhibitors and thyroid replacement therapy.

Drugs that may increase or decrease blood-glucose-lowering effect: Beta-adrenergic blockers, clonidine, lithium salts, and alcohol. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

Drugs that may mask the signs of hypoglycemia: Beta-adrenergic blockers, clonidine, guanethidine, and reserpine.

4.6 Use in special populations
Renal or Hepatic Impairment: Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment.

Use in Pregnancy: Pregnancy Category B. All pregnancies have a background risk of birth defects, miscarriage, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and is decreased with good glucose control. It is important for patients to maintain good control of diabetes before conception and during pregnancy. Special attention should be paid to diet, exercise and insulin regimens. Insulin requirements may decrease during the first trimester, usually increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking WOSULIN-30/70. While there are no adequate and well-controlled studies of WOSULIN-30/70 in pregnant women, evidence from published literature suggests that good glycemic control in patients with diabetes during pregnancy provides significant maternal and fetal benefits.

Labor and Delivery: Careful glucose monitoring and management of patients with diabetes during labor and delivery are required.

Nursing Mothers: Endogenous insulin is present in human milk. Insulin orally ingested is degraded in the gastrointestinal tract. No adverse reactions have been associated with infant exposure to insulin through the consumption of human milk. Good glucose control supports lactation in patients with diabetes. Women with diabetes who are lactating may require adjustments in their insulin dose.

Pediatric Use: Safety and effectiveness of WOSULIN-30/70 in patients less than 18 years of age has not been established.

Geriatric Use: The effect of age on the pharmacokinetics and pharmacodynamics of WOSULIN-30/70 has not been studied. Patients with advanced age using any insulin, including WOSULIN-30/70, may be at increased risk of hypoglycemia due to co-morbid disease and polypharmacy.

4.7 Effects on ability to drive and use machines
The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery). Patients should therefore be advised to avoid hypoglycemia during driving. This is particularly significant in patients who have reduced awareness of the warning signs of hypoglycemia or have frequent episodes of hypoglycemia.

4.8 Undesirable effects

Hypoglycemia: Hypoglycemia is the most frequent adverse events experienced by insulin users. Symptoms of mild to moderate hypoglycemia may occur suddenly and can include sweating, drowsiness, dizziness, sleep disturbances, palpitation, anxiety, tremor, blurred vision, hunger, slurred speech, restlessness, depressed mood, tingling in the hands, feet, lips, or tongue, irritability, lightheadedness, abnormal behavior, inability to concentrate, unsteady movement, headache and personality changes. Signs of severe hypoglycemia can include disorientation, seizures, unconsciousness, coma and death.

Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as long duration of diabetes, autonomic diabetic neuropathy, use of medications such as beta-adrenergic blockers, changing insulin preparations, or intensified control (3 or more insulin injections per day) of diabetes. Without recognition of early warning symptoms, the patient may not be able to take steps to avoid more serious hypoglycemia. Patients who experience hypoglycemia without early warning symptoms should monitor their blood glucose more frequently, especially prior to activities such as driving. Mild to moderate hypoglycemia may be treated by eating foods or taking drinks that contain sugar. Patients should always carry a quick source of sugar, such as hard candy, non-diet carbohydrate-containing drinks or glucose tablets.

Hypokalemia: See section 4.4 Special warnings and precautions for use.

Lipodystrophy: Administration of insulin subcutaneously can result in lipodystrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue).

Allergy

Local Allergy – Patients occasionally experience erythema, local edema, and pruritus at the site of injection. This condition usually is self-limiting. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.

Systemic Allergy – Less commonly, but potentially more serious, is generalized allergy to insulin, which may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalized allergy (anaphylaxis) may be life threatening.

Weight Gain: Weight gain can occur with some insulin therapies and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.

Peripheral Edema: Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Immunogenicity: Development of antibodies that react with human insulin have been observed with all insulin, including WOSULIN-30/70.

Insulin resistance: When insulin requirements is increased (> 200 IU / day), insulin resistance is said to have developed. The following are the different grades of insulin resistance:

Acute:

Acute insulin resistance develops rapidly and is usually a short term problem. It usually occurs due to an underlying infection, trauma, surgery and emotional stress. Treatment is to overcome the precipitating factor and to give high doses of regular insulin.

Chronic:

This type of insulin resistance is generally seen in patients treated for years with conventional preparations of beef or pork insulins and it is more common in patients with Type 2 diabetes. Development of such a type of insulin resistance is an indication for switching patients to the newer preparations of insulin. After instituting the newer preparations, insulin requirement gradually declines over weeks and months and majority of patients stabilize at approximately 60 IU / day.

4.9 Overdose

Excess insulin may cause hypoglycemia and hypokalemia, particularly after intravenous administration. Hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy expenditure, or both. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes of coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

5. Pharmacological properties

5.1 Mechanism of Action

Regulation of glucose metabolism is the primary activity of insulin. Insulin lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat following binding to the insulin receptors, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis, proteolysis, and gluconeogenesis, and enhance protein synthesis and conversion of excess glucose into fat.

5.2 Pharmacodynamic properties

The prime activity of insulin is the regulation of glucose metabolism. In addition insulin has several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.

5.3 Pharmacokinetic properties

WOSULIN-30/70 combines an intermediate-acting insulin with the more rapid onset of action of regular human insulin. The time course of action of insulin, such as WOSULIN-30/70 may vary in different individuals and in different situations. The rate of insulin absorption and consequently the onset of activity is known to be affected by the site of injection, physical activity level, and other variables. With subcutaneous use, the pharmacologic effect of WOSULIN-30/70 begins approximately 30 minutes after administration. The effect is maximal between approximately 2-12 hours and duration of effect is for approximately 18-24 hours. The uptake and degradation of insulin occurs predominantly in liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in the clearance of insulin.

6. Nonclinical properties

6.1 Animal Toxicology

Single dose toxicity – There were no signs of toxicity in Swiss albino mice and Sprague Dawley rats treated at the dose level of 240IU/kg body weight of subcutaneous injections of Biphasic isophane insulin.

Repeated dose toxicity – There were no signs of toxicity in Swiss albino mice and Sprague Dawley rats during a period of 28 days with subcutaneous injections of Biphasic isophane insulin.

Dermal Toxicity – There were no signs of dermal irritation or skin sensitization in New Zealand white rabbits and Duncan Hartley guinea pigs with topical testing of Biphasic isophane insulin.

Carcinogenicity and impairment of fertility: Carcinogenicity and fertility studies were not performed in animals.

Mutagenicity - Human insulin was not mutagenic in mammalian cells and tested negative in the Ames bacterial reverse mutation assay with and without activation.

7. Description

WOSULIN-30/70 (30% human insulin injection and 70% human insulin isophane suspension [rDNA origin]) is a human insulin suspension. Human insulin is synthesized in a laboratory strain of *Hansenula polymorpha* (a yeast), in which the gene for human insulin has been inserted by the recombinant DNA technique. WOSULIN-30/70 is a suspension of crystals produced from combining human insulin and protamine sulfate under appropriate conditions for crystal formation and mixing with human insulin injection.

8. Pharmaceutical particulars

8.1 Incompatibilities

These medicinal products should not be mixed with any other insulin or any other medicinal product.

8.2 Shelf-life

36 months

8.3 Packaging information

PACK: WOSULIN-30/70 100 IU/ml – 3 mL multi-dose cartridge

8.4 Storage and handling instructions

WOSULIN-30/70 cartridge when not in use should be stored in a refrigerator (2°C to 8°C) but not allowed to freeze. When in use, cartridges may be kept at room temperature up to 30 °C for up to four weeks. Do not expose to excessive heat or direct sunlight. WOSULIN-30/70 must be kept out of reach of children. Insulin preparations, which have been frozen, must not be used. Once opened, insulin is kept at room temperature. Cold insulin can be irritating to inject. Remove the needle after each injection, otherwise temperature changes may cause liquid to leak out of the needle and the insulin concentration may increase. Do not refill the Cartridge. Do not use WOSULIN-30/70 cartridge after the expiration date stamped on the label or if it has been frozen.

9. Patient Counselling Information

Important Risks and Adverse drug reactions

Never Share a Wosulin 30/70 cartridge or syringe between patients

Advise patients using Wosulin 30/70 cartridge, not to share needles, syringes, or DispoPen with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of Wosulin 30/70 therapy. Instruct patients on handling of special situations such as illness, stress, or emotional disturbances, an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals.

Instruct patients on the management of hypoglycemia. Advise patients to regularly carry some sugar lumps, sweets, biscuits, or sugary fruit juice to mitigate symptoms of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery. (see Special warnings and precautions for use 4.7).

Hypoglycemia due to Medication Errors

Instruct patients that hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy expenditure, or both. Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products.

Hypersensitivity Reactions

Advise patients that hypersensitivity reactions can occur with Wosulin. Inform patients on the symptoms of hypersensitivity reactions and advise the patient to discontinue Wosulin and to seek medical attention if they occur (see Undesirable effects (4.8)).

Use in Special Population

Pregnant females

Advise pregnant patients that insulin requirements usually fall during the first trimester and increase during second and third trimesters of pregnancy. Careful monitoring is required throughout pregnancy. During the perinatal period, careful monitoring of infants born to mothers with diabetes is warranted.

Nursing Mothers

Advise the nursing mothers that dosage of insulin may be reduced.

Renal and Hepatic Impairment

Advise the patients that dosage of insulin may be reduced and these patients are at increased risk of hypoglycemia thus requiring frequent blood glucose monitoring.

Administration Instructions

Instruct the patient to never use Wosulin 30/70 cartridge if it is frozen. Advise the patients on proper and safe disposal of the needle (see Instructions for use).

Storage and Handling

Instruct the patient that Wosulin 30/70 cartridge which is not in use, should be stored in a refrigerator (2°C to 8°C) and should never be kept in the freezer compartment. Instruct the patient that when in use, Wosulin 30/70 cartridge may be carried at room temperature up to 30°C for up to 4 weeks.

10. Details of manufacturer

Manufactured in India by
WOCKHARDT LIMITED Biotech Park, H-14/2 MIDC, Waluj, Aurangabad 431136 Maharashtra State

11. Details of permission or licence number

Manufacturing Licence No: AD/004

12. Date of revision

Jan/2020.

® Registered Trademarks of Wockhardt

L1No. m-5302/2
22/06/7

Front

Back

ACTUAL SIZE 110 X 218 MM
(WOSULIN-30-70)

Folding Size: 110 x 25

Pantone 471 U

K 100